FDA label 8e19d4a9-5644-40f4-a356-718baefc4f64
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- SPL set ID
- aa756b80-11eb-4f67-abb8-8babcee728b2
- SPL ID
- 8e19d4a9-5644-40f4-a356-718baefc4f64
- Version
- 12
- Effective date
- 2012-08-07
- Source export date
- 2026-10-12
- Source partition
- 8
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0008-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-10-12/fa098e7c5cff0b1ab653ce934059d1f4b90b860bafc0383a1f66223ce1037518/drug-label-0008-of-0014.json.zip
- Source manifest SHA-256
- 7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
- Import run
- 20261013T011858Z
- Imported at
- 2026-10-13 02:07:47
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| spl id | 8e19d4a9-5644-40f4-a356-718baefc4f64 | id | |
| spl set id | aa756b80-11eb-4f67-abb8-8babcee728b2 | set_id |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING Increased susceptibility to infection and the possible development of lymphoma may result from immunosuppression. Only physicians experienced in immunosuppressive therapy and management of organ transplant patients should prescribe tacrolimus capsules. Patients receiving the drug should be managed in facilities equipped and staffed with adequate laboratory and supportive medical resources. The physician responsible for maintenance therapy should have complete information requisite for the follow-up of the patient.
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings
WARNINGS (See boxed WARNING. ) Post-Transplant Diabetes Mellitus Insulin-dependent post-transplant diabetes mellitus (PTDM) was reported in 20% of tacrolimus-treated kidney transplant patients without pretransplant history of diabetes mellitus in the Phase III study (See Tables Below). The median time to onset of PTDM was 68 days. Insulin dependence was reversible in 15% of these PTDM patients at one year and in 50% at 2 years post transplant. Black and Hispanic kidney transplant patients were at an increased risk of development of PTDM. Incidence of Post Transplant Diabetes Mellitus and Insulin Use at 2 Years in Kidney Transplant Recipients in the Phase III study Status of PTDM a Tacrolimus CBIR a) use of insulin for 30 or more consecutive days, with < 5 day gap, without a prior history of insulin dependent diabetes mellitus or non insulin dependent diabetes mellitus. Patients without pretransplant history of diabetes mellitus. 151 151 New onset PTDM a , 1st Year 30/151 (20%) 6/151 (4%) Still insulin dependent at one year in those without prior history of diabetes. 25/151 (17%) 5/151 (3%) New onset PTDM a post 1 year 1 0 Patients with PTDM a at 2 years 16/151 (11%) 5/151 (3%) Development of Post Transplant Diabetes Mellitus by Race and by Treatment Group during First Year Post Kidney Transplantation in the Phase III study Patient Race Tacrolimus CBIR No. of Patients at Risk Patients Who Developed PTDM a No. of Patients At Risk Patients Who Developed PTDM a a) use of insulin for 30 or more consecutive days, with < 5 day gap, without a prior history of insulin dependent diabetes mellitus or non insulin dependent diabetes mellitus. Black 41 15 (37%) 36 3 (8%) Hispanic 17 5 (29%) 18 1 (6%) Caucasian 82 10 (12%) 87 1 (1%) Other 11 0 (0%) 10 1 (10%) Total 151 30 (20%) 151 6 (4%) Insulin-dependent post-transplant diabetes mellitus was reported in 18% and 11% of tacrolimus-treated liver transplant patients and was reversible in 45% and 31% of these patients at 1 year post transplant, in the U.S. and European randomized studies, respectively (See Table below ). Hyperglycemia was associated with the use of tacrolimus in 47% and 33% of liver transplant recipients in the U.S. and European randomized studies, respectively, and may require treatment (see ADVERSE REACTIONS ). Incidence of Post Transplant Diabetes Mellitus and Insulin Use at 1 Year in Liver Transplant Recipients Status of PTDM a US Study European Study Tacrolimus CBIR Tacrolimus CBIR a) use of insulin for 30 or more consecutive days, with < 5 day gap, without a prior history of insulin dependent diabetes mellitus or non insulin dependent diabetes mellitus. b) Patients without pretransplant history of diabetes mellitus. Patients at risk b 239 236 239 249 New Onset PTDM a 42 (18%) 30 (13%) 26 (11%) 12 (5%) Patients still on insulin at 1 year 23 (10%) 19 (8%) 18 (8%) 6 (2%) Nephrotoxicity Tacrolimus can cause nephrotoxicity, particularly when used in high doses. Nephrotoxicity was reported in approximately 52% of kidney transplantation patients and in 40% and 36% of liver transplantation patients receiving tacrolimus in the U.S. and European randomized trials, respectively. (see ADVERSE REACTIONS ). More overt nephrotoxicity is seen early after transplantation, characterized by increasing serum creatinine and a decrease in urine output. Patients with impaired renal function should be monitored closely as the dosage of tacrolimus capsules may need to be reduced. In patients with persistent elevations of serum creatinine who are unresponsive to dosage adjustments, consideration should be given to changing to another immunosuppressive therapy. Care should be taken in using tacrolimus with other nephrotoxic drugs. In particular, to avoid excess nephrotoxicity, tacrolimus capsules should not be used simultaneously with cyclosporine. Tacrolimus capsules or cyclosporine should be discontinued at least 24 hours prior to initiating the other. In the presence of elevated tacrolimus or cyclosporine concentrations, dosing with the other drug usually should be further delayed. Hyperkalemia Mild to severe hyperkalemia was reported in 31% of kidney transplant recipients and in 45% and 13% of liver transplant recipients treated with tacrolimus in the U.S. and European randomized trials, respectively, and may require treatment (see ADVERSE REACTIONS ). Serum potassium levels should be monitored and potassium-sparing diuretics should not be used during tacrolimus therapy ( see PRECAUTIONS ) . Neurotoxicity Tacrolimus can cause neurotoxicity, particularly when used in high doses. Neurotoxicity, including tremor, headache, and other changes in motor function, mental status, and sensory function were reported in approximately 55% of liver transplant recipients in the two randomized studies. Tremor occurred more often in tacrolimus-treated kidney transplant patients (54%) compared to cyclosporine-treated patients. The incidence of other neurological events in kidney transplant patients was similar in the two treatment groups (see ADVERSE REACTIONS ). Tremor and headache have been associated with high whole-blood concentrations of tacrolimus and may respond to dosage adjustment. Seizures have occurred in adult and pediatric patients receiving tacrolimus (see ADVERSE REACTIONS ). Coma and delirium also have been associated with high plasma concentrations of tacrolimus. Patients treated with tacrolimus have been reported to develop posterior reversible encephalopathy syndrome (PRES). Symptoms indicating PRES include headache, altered mental status, seizures, visual disturbances and hypertension. Diagnosis may be confirmed by radiological procedure. If PRES is suspected or diagnosed, blood pressure control should be maintained and immediate reduction of immunosuppression is advised. This syndrome is characterized by reversal of symptoms upon reduction or discontinuation of immunosuppression. Malignancy and Lymphoproliferative Disorders As in patients receiving other immunosuppressants, patients receiving tacrolimus are at increased risk of developing lymphomas and other malignancies, particularly of the skin. The risk appears to be related to the intensity and duration of immunosuppression rather than to the use of any specific agent. A lymphoproliferative disorder (LPD) related to Epstein-Barr Virus (EBV) infection has been reported in immunosuppressed organ transplant recipients. The risk of LPD appears greatest in young children who are at risk for primary EBV infection while immunosuppressed or who are switched to tacrolimus following long-term immunosuppression therapy. Because of the danger of oversuppression of the immune system which can increase susceptibility to infection, combination immunosuppressant therapy should be used with caution. Latent Viral Infections Immunosuppressed patients are at increased risk for opportunistic infections, including activation of latent viral infections. These include BK virus associated nephropathy and JC virus associated progressive multifocal leukoencephalopathy (PML) which have been observed in patients receiving tacrolimus. These infections may lead to serious, including fatal, outcomes. Anaphylactic Reactions A few patients receiving tacrolimus injection have experienced anaphylactic reactions. Although the exact cause of these reactions is not known, other drugs with castor oil derivatives in the formulation have been associated with anaphylaxis in a small percentage of patients. Because of this potential risk of anaphylaxis, tacrolimus injection should be reserved for patients who are unable to take tacrolimus capsules. Patients receiving tacrolimus injection should be under continuous observation for at least the first 30 minutes following the start of the infusion and at frequent intervals thereafter. If signs or symptoms of anaphylaxis occur, the infusion should be stopped. An aqueous solution of epinephrine should be available at the bedside as well as a source of oxygen.
warnings table
<table frame="void"> <caption>Incidence of Post Transplant Diabetes Mellitus and Insulin Use at 2 Years in Kidney Transplant Recipients in the Phase III study</caption> <col/> <col/> <col/> <thead> <tr> <td valign="top" styleCode=" Botrule Lrule Rrule "> <content styleCode="bold">Status of PTDM</content> <sup>a</sup> </td> <td align="center" valign="top" styleCode=" Botrule Lrule Rrule "> <content styleCode="bold">Tacrolimus</content> </td> <td align="center" valign="top" styleCode=" Botrule Lrule Rrule "> <content styleCode="bold">CBIR</content> </td> </tr> </thead> <tfoot> <tr> <td valign="top" colspan="3"> a) use of insulin for 30 or more consecutive days, with < 5 day gap, without a prior history of insulin dependent diabetes mellitus or non insulin dependent diabetes mellitus. </td> </tr> </tfoot> <tbody> <tr> <td valign="top" styleCode=" Botrule Toprule Lrule Rrule "> Patients without pretransplant history of diabetes mellitus.</td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 151</td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 151</td> </tr> <tr> <td valign="top" styleCode=" Botrule Toprule Lrule Rrule "> New onset PTDM<sup>a</sup>, 1st Year</td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 30/151 (20%)</td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 6/151 (4%)</td> </tr> <tr> <td valign="top" styleCode=" Botrule Toprule Lrule Rrule "> Still insulin dependent at one year in those without prior history of diabetes.</td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 25/151 (17%)</td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 5/151 (3%)</td> </tr> <tr> <td valign="top" styleCode=" Botrule Toprule Lrule Rrule "> New onset PTDM<sup>a</sup> post 1 year</td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 1</td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 0</td> </tr> <tr> <td valign="top" styleCode=" Toprule Lrule Rrule "> Patients with PTDM<sup>a</sup> at 2 years</td> <td align="center" valign="top" styleCode=" Toprule Lrule Rrule "> 16/151 (11%)</td> <td align="center" valign="top" styleCode=" Toprule Lrule Rrule "> 5/151 (3%)</td> </tr> </tbody> </table>
warnings table
<table frame="void"> <caption>Development of Post Transplant Diabetes Mellitus by Race and by Treatment Group during First Year Post Kidney Transplantation in the Phase III study</caption> <col/> <col/> <col/> <col/> <col/> <thead> <tr> <td valign="top" styleCode=" Lrule Rrule "> <content styleCode="bold">Patient Race</content> </td> <td align="center" valign="top" colspan="2" styleCode=" Botrule Lrule Rrule "> <content styleCode="bold">Tacrolimus</content> </td> <td align="center" valign="top" colspan="2" styleCode=" Botrule Lrule Rrule "> <content styleCode="bold">CBIR</content> </td> </tr> <tr> <td valign="top" styleCode=" Botrule Lrule Rrule "> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">No. of Patients at Risk</content> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Patients Who Developed PTDM</content> <sup>a</sup> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">No. of Patients At Risk</content> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Patients Who Developed PTDM</content> <sup>a</sup> </td> </tr> </thead> <tfoot> <tr> <td valign="top" colspan="5"> a) use of insulin for 30 or more consecutive days, with < 5 day gap, without a prior history of insulin dependent diabetes mellitus or non insulin dependent diabetes mellitus. </td> </tr> </tfoot> <tbody> <tr> <td valign="top" styleCode=" Botrule Toprule Lrule Rrule "> Black </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 41 </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 15 (37%) </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 36 </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 3 (8%)</td> </tr> <tr> <td valign="top" styleCode=" Botrule Toprule Lrule Rrule "> Hispanic </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 17 </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 5 (29%) </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 18 </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 1 (6%)</td> </tr> <tr> <td valign="top" styleCode=" Botrule Toprule Lrule Rrule "> Caucasian </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 82 </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 10 (12%) </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 87 </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 1 (1%)</td> </tr> <tr> <td valign="top" styleCode=" Botrule Toprule Lrule Rrule "> Other </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 11 </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 0 (0%) </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 10 </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 1 (10%)</td> </tr> <tr> <td valign="top" styleCode=" Toprule Lrule Rrule "> Total </td> <td align="center" valign="top" styleCode=" Toprule Lrule Rrule "> 151</td> <td align="center" valign="top" styleCode=" Toprule Lrule Rrule "> 30 (20%) </td> <td align="center" valign="top" styleCode=" Toprule Lrule Rrule "> 151 </td> <td align="center" valign="top" styleCode=" Toprule Lrule Rrule "> 6 (4%)</td> </tr> </tbody> </table>
warnings table
<table frame="void"> <caption>Incidence of Post Transplant Diabetes Mellitus and Insulin Use at 1 Year in Liver Transplant Recipients</caption> <col/> <col/> <col/> <col/> <col/> <thead> <tr> <td rowspan="2" styleCode=" Botrule Lrule Rrule "> <content styleCode="bold">Status of PTDM<sup>a</sup> </content> </td> <td align="center" valign="top" colspan="2" styleCode=" Botrule Lrule Rrule "> <content styleCode="bold">US Study</content> </td> <td align="center" valign="top" colspan="2" styleCode=" Botrule Lrule Rrule "> <content styleCode="bold">European Study</content> </td> </tr> <tr> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Tacrolimus</content> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">CBIR</content> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">Tacrolimus</content> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> <content styleCode="bold">CBIR</content> </td> </tr> </thead> <tfoot> <tr> <td valign="top" colspan="5"> a) use of insulin for 30 or more consecutive days, with < 5 day gap, without a prior history of insulin dependent diabetes mellitus or non insulin dependent diabetes mellitus. </td> </tr> <tr> <td valign="top" colspan="5"> b) Patients without pretransplant history of diabetes mellitus. </td> </tr> </tfoot> <tbody> <tr> <td valign="top" styleCode=" Botrule Toprule Lrule Rrule "> Patients at risk<sup>b</sup> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 239</td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 236</td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 239</td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 249</td> </tr> <tr> <td valign="top" styleCode=" Botrule Toprule Lrule Rrule "> New Onset PTDM<sup>a</sup> </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 42 (18%) </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 30 (13%) </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 26 (11%) </td> <td align="center" valign="top" styleCode=" Botrule Toprule Lrule Rrule "> 12 (5%)</td> </tr> <tr> <td valign="top" styleCode=" Toprule Lrule Rrule "> Patients still on insulin at 1 year </td> <td align="center" valign="top" styleCode=" Toprule Lrule Rrule "> 23 (10%) </td> <td align="center" valign="top" styleCode=" Toprule Lrule Rrule "> 19 (8%) </td> <td align="center" valign="top" styleCode=" Toprule Lrule Rrule "> 18 (8%) </td> <td align="center" valign="top" styleCode=" Toprule Lrule Rrule "> 6 (2%)</td> </tr> </tbody> </table>
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS Liver Transplantation The principal adverse reactions of tacrolimus are tremor, headache, diarrhea, hypertension, nausea, and abnormal renal function. These occur with oral and IV administration of tacrolimus and may respond to a reduction in dosing. Diarrhea was sometimes associated with other gastrointestinal complaints such as nausea and vomiting. Hyperkalemia and hypomagnesemia have occurred in patients receiving tacrolimus therapy. Hyperglycemia has been noted in many patients; some may require insulin therapy (see WARNINGS ). The incidence of adverse events was determined in two randomized comparative liver transplant trials among 514 patients receiving tacrolimus and steroids and 515 patients receiving a cyclosporine-based regimen (CBIR). The proportion of patients reporting more than one adverse event was 99.8% in the tacrolimus group and 99.6% in the CBIR group. Precautions must be taken when comparing the incidence of adverse events in the U.S. study to that in the European study. The 12-month post-transplant information from the U.S. study and from the European study is presented below. The two studies also included different patient populations and patients were treated with immunosuppressive regimens of differing intensities. Adverse events reported in ≥ 15% in tacrolimus patients (combined study results) are presented below for the two controlled trials in liver transplantation: LIVER TRANSPLANTATION: ADVERSE EVENTS OCCURRING IN ≥ 15% OF TACROLIMUS-TREATED PATIENTS U.S. STUDY EUROPEAN STUDY Tacrolimus (N=250) CBIR (N=250) Tacrolimus (N=264) CBIR (N=265) Nervous System Headache (see WARNINGS ) 64% 60% 37% 26% Tremor (see WARNINGS ) 56% 46% 48% 32% Insomnia 64% 68% 32% 23% Paresthesia 40% 30% 17% 17% Gastrointestinal Diarrhea 72% 47% 37% 27% Nausea 46% 37% 32% 27% Constipation 24% 27% 23% 21% LFT Abnormal 36% 30% 6% 5% Anorexia 34% 24% 7% 5% Vomiting 27% 15% 14% 11% Cardiovascular Hypertension (see PRECAUTIONS ) 47% 56% 38% 43% Urogenital Kidney Function Abnormal (see WARNINGS ) 40% 27% 36% 23% Creatinine Increased (see WARNINGS ) 39% 25% 24% 19% BUN Increased (see WARNINGS ) 30% 22% 12% 9% Urinary Tract Infection 16% 18% 21% 19% Oliguria 18% 15% 19% 12% Metabolic and Nutritional Hyperkalemia (see WARNINGS ) 45% 26% 13% 9% Hypokalemia 29% 34% 13% 16% Hyperglycemia (see WARNINGS ) 47% 38% 33% 22% Hypomagnesemia 48% 45% 16% 9% Hemic and Lymphatic Anemia 47% 38% 5% 1% Leukocytosis 32% 26% 8% 8% Thrombocytopenia 24% 20% 14% 19% Miscellaneous Abdominal Pain 59% 54% 29% 22% Pain 63% 57% 24% 22% Fever 48% 56% 19% 22% Asthenia 52% 48% 11% 7% Back Pain 30% 29% 17% 17% Ascites 27% 22% 7% 8% Peripheral Edema 26% 26% 12% 14% Respiratory System Pleural Effusion 30% 32% 36% 35% Atelectasis 28% 30% 5% 4% Dyspnea 29% 23% 5% 4% Skin and Appendages Pruritus 36% 20% 15% 7% Rash 24% 19% 10% 4% Less frequently observed adverse reactions in both liver transplantation and kidney transplantation patients are described under the subsection Less Frequently Reported Adverse Reactions below. Kidney Transplantation The most common adverse reactions reported were infection, tremor, hypertension, abnormal renal function, constipation, diarrhea, headache, abdominal pain and insomnia. Adverse events that occurred in ≥15% of kidney transplant patients treated with tacrolimus in conjunction with azathioprine are presented below: KIDNEY TRANSPLANTATION: ADVERSE EVENTS OCCURRING IN ≥ 15% OF PATIENTS TREATED WITH TACROLIMUS IN CONJUNCTION WITH AZATHIOPRINE Tacrolimus (N=205) CBIR (N=207) Nervous System Tremor (see WARNINGS ) 54% 34% Headache (see WARNINGS ) 44% 38% Insomnia 32% 30% Paresthesia 23% 16% Dizziness 19% 16% Gastrointestinal Diarrhea 44% 41% Nausea 38% 36% Constipation 35% 43% Vomiting 29% 23% Dyspepsia 28% 20% Cardiovascular Hypertension (see PRECAUTIONS ) 50% 52% Chest pain 19% 13% Urogenital Creatinine Increased (see WARNINGS ) 45% 42% Urinary Tract Infection 34% 35% Metabolic and Nutritional Hypophosphatemia 49% 53% Hypomagnesemia 34% 17% Hyperlipemia 31% 38% Hyperkalemia (see WARNINGS ) 31% 32% Diabetes Mellitus (see WARNINGS ) 24% 9% Hypokalemia 22% 25% Hyperglycemia (see WARNINGS ) 22% 16% Edema 18% 19% Hemic and Lymphatic Anemia 30% 24% Leukopenia 15% 17% Miscellaneous Infection 45% 49% Peripheral Edema 36% 48% Asthenia 34% 30% Abdominal Pain 33% 31% Pain 32% 30% Fever 29% 29% Back Pain 24% 20% Respiratory System Dyspnea 22% 18% Cough Increased 18% 15% Musculoskeletal Arthralgia 25% 24% Skin Rash 17% 12% Pruritus 15% 7% Adverse events that occurred in ≥ 10% of kidney transplant patients treated with tacrolimus in conjunction with MMF in Study 1* are presented below: KIDNEY TRANSPLANTATION: ADVERSE EVENTS OCCURRING IN ≥ 10% OF TACROLIMUS-TREATED PATIENTS Tacrolimus (Group C) (N=403) Cyclosporine (Group A) (N=384) Cyclosporine (Group B) (N=408) *Study 1 was conducted entirely outside of the United States. Such studies often report a lower incidence of adverse events in comparison to US studies. Anemia 17% 19% 17% Leucopenia 13% 10% 10% Diarrhea 25% 16% 13% Edema peripheral 11% 12% 13% Urinary tract infection 24% 28% 24% Hyperlipidemia 10% 15% 13% Hypertension (see PRECAUTIONS ) 13% 14% 12% Adverse events that occurred in ≥15% of kidney transplant patients treated with tacrolimus in conjunction with MMF in Study 2 are presented below: KIDNEY TRANSPLANTATION: ADVERSE EVENTS OCCURRING IN ≥ 15% OF TACROLIMUS-TREATED PATIENTS Tacrolimus (N=212) Cyclosporine (N=212) Gastrointestinal Disorders Diarrhea 44% 26% Nausea 39% 47% Constipation 36% 41% Vomiting 26% 25% Dyspepsia 18% 15% Injury, Poisoning, and Procedural Complications Post Procedural Pain 29% 27% Incision Site Complication 28% 23% Graft Dysfunction 24% 18% Metabolism and Nutrition Disorders Hypomagnesemia 28% 22% Hypophosphatemia 28% 21% Hyperkalemia (see WARNINGS ) 26% 19% Hyperglycemia (see WARNINGS ) 21% 15% Hyperlipidemia 18% 25% Hypokalemia 16% 18% Nervous System Disorders Tremor 34% 20% Headache 24% 25% Blood and Lymphatic System Disorders Anemia 30% 28% Leukopenia 16% 12% Miscellaneous Edema Peripheral 35% 46% Hypertension (see PRECAUTIONS ) 32% 35% Insomnia 30% 21% Urinary Tract Infection 26% 22% Blood creatinine increased 23% 23% Less frequently observed adverse reactions in both liver transplantation and kidney transplantation patients are described under the subsection Less Frequently Reported Adverse Reactions shown below. Less Frequently Reported Adverse Reactions The following adverse events were reported in either liver and/or kidney transplant recipients who were treated with tacrolimus in clinical trials. Nervous System (see WARNINGS ) Abnormal dreams, agitation, amnesia, anxiety, confusion, convulsion, crying, depression, dizziness, elevated mood, emotional lability, encephalopathy, hemorrhagic stroke, hallucinations, headache, hypertonia, incoordination, insomnia, monoparesis, myoclonus, nerve compression, nervousness, neuralgia, neuropathy, paresthesia, paralysis flaccid, psychomotor skills impaired, psychosis, quadriparesis, somnolence, thinking abnormal, vertigo, writing impaired Special Senses Abnormal vision, amblyopia, ear pain, otitis media, tinnitus Gastrointestinal Anorexia, cholangitis, cholestatic jaundice, diarrhea, duodenitis, dyspepsia, dysphagia, esophagitis, flatulence, gastritis, gastroesophagitis, gastrointestinal hemorrhage, GGT increase, GI disorder, GI perforation, hepatitis, hepatitis granulomatous, ileus, increased appetite, jaundice, liver damage, liver function test abnormal, nausea, nausea and vomiting, esophagitis ulcerative, oral moniliasis, pancreatic pseudocyst, rectal disorder, stomatitis, vomiting Cardiovascular Abnormal ECG, angina pectoris, arrhythmia, atrial fibrillation, atrial flutter, bradycardia, cardiac fibrillation, cardiopulmonary failure, cardiovascular disorder, chest pain, congestive heart failure, deep thrombophlebitis, echocardiogram abnormal, electrocardiogram QRS complex abnormal, electrocardiogram ST segment abnormal, heart failure, heart rate decreased, hemorrhage, hypotension, peripheral vascular disorder, phlebitis, postural hypotension, syncope, tachycardia, thrombosis, vasodilatation Urogenital (see WARNINGS ) Acute kidney failure, albuminuria, BK nephropathy, bladder spasm, cystitis, dysuria, hematuria, hydronephrosis, kidney failure, kidney tubular necrosis, nocturia, oliguria, pyuria, toxic nephropathy, urge incontinence, urinary frequency, urinary incontinence, urinary retention, vaginitis Metabolic/Nutritional Acidosis, alkaline phosphatase increased, alkalosis, ALT (SGPT) increased, AST (SGOT) increased, bicarbonate decreased, bilirubinemia, BUN increased, dehydration, edema, GGT increased, gout, healing abnormal, hypercalcemia, hypercholesterolemia, hyperkalemia, hyperlipemia, hyperphosphatemia, hyperuricemia, hypervolemia, hypocalcemia, hypoglycemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, hypoproteinemia, lactic dehydrogenase increase, peripheral edema, weight gain Endocrine (see PRECAUTIONS ) Cushing’s syndrome, diabetes mellitus Hemic/Lymphatic Coagulation disorder, ecchymosis, hematocrit increased, hemoglobin abnormal, hypochromic anemia, leukocytosis, leukopenia, polycythemia, prothrombin decreased, serum iron decreased, thrombocytopenia Miscellaneous Abdomen enlarged, abdominal pain, abscess, accidental injury, allergic reaction, asthenia, back pain, cellulitis, chills, fall, feeling abnormal, fever, flu syndrome, generalized edema, hernia, mobility decreased, pain, peritonitis, photosensitivity reaction, sepsis, temperature intolerance, ulcer Musculoskeletal Arthralgia, cramps, generalized spasm, joint disorder, leg cramps, myalgia, myasthenia, osteoporosis Respiratory Asthma, bronchitis, cough increased, dyspnea, emphysema, hiccups, lung disorder, lung function decreased, pharyngitis, pleural effusion, pneumonia, pneumothorax, pulmonary edema, respiratory disorder, rhinitis, sinusitis, voice alteration Skin Acne, alopecia, exfoliative dermatitis, fungal dermatitis, herpes simplex, herpes zoster, hirsutism, neoplasm skin benign, skin discoloration, skin disorder, skin ulcer, sweating. Post Marketing Post Marketing Adverse Events The following adverse events have been reported from worldwide marketing experience with tacrolimus. Because these events are reported voluntarily from a population of uncertain size, are associated with concomitant diseases and multiple drug therapies and surgical procedures, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Decisions to include these events in labeling are typically based on one or more of the following factors: (1) seriousness of the event, (2) frequency of the reporting, or (3) strength of causal connection to the drug. There have been rare spontaneous reports of myocardial hypertrophy associated with clinically manifested ventricular dysfunction in patients receiving tacrolimus therapy (see PRECAUTIONS-Myocardial Hypertrophy ). Other events include: Cardiovascular Atrial fibrillation, atrial flutter, cardiac arrhythmia, cardiac arrest, electrocardiogram T wave abnormal, flushing, myocardial infarction, myocardial ischemia, pericardial effusion, QT prolongation, Torsade de Pointes, venous thrombosis deep limb, ventricular extrasystoles, ventricular fibrillation Gastrointestinal Bile duct stenosis, colitis, enterocolitis, gastroenteritis, gastrooesophageal reflux disease, hepatic cytolysis, hepatic necrosis, hepatotoxicity, impaired gastric emptying, liver fatty, mouth ulceration, pancreatitis hemorrhagic, pancreatitis necrotizing, stomach ulcer, venoocclusive liver disease Hemic/Lymphatic Disseminated intravascular coagulation, neutropenia, pancytopenia, thrombocytopenic purpura, thrombotic thrombocytopenic purpura Metabolic/Nutritional Glycosuria, increased amylase including pancreatitis, weight decreased Miscellaneous Feeling hot and cold, feeling jittery, hot flushes, multi-organ failure, primary graft dysfunction Nervous System Carpal tunnel syndrome, cerebral infarction, hemiparesis, leukoencephalopathy, mental disorder, mutism, posterior reversible encephalopathy syndrome (PRES), progressive multifocal leukoencephalopathy (PML), quadriplegia, speech disorder, syncope Respiratory Acute respiratory distress syndrome, interstitial lung disease, lung infiltration, respiratory distress, respiratory failure Skin Stevens-Johnson syndrome, toxic epidermal necrolysis Special Senses Blindness, blindness cortical, hearing loss including deafness, photophobia Urogenital Acute renal failure, cystitis hemorrhagic, hemolytic-uremic syndrome, micturition disorder.
adverse reactions table
<table frame="void"> <caption> LIVER TRANSPLANTATION: ADVERSE EVENTS OCCURRING IN ≥ 15% OF TACROLIMUS-TREATED PATIENTS</caption> <col/> <col/> <col/> <col/> <col/> <thead> <tr> <td valign="top" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule "> </td> <td valign="top" colspan="2" styleCode=" Botrule Toprule Lrule Rrule "> U.S. STUDY </td> <td valign="top" colspan="2" styleCode=" Botrule Toprule Lrule Rrule "> EUROPEAN STUDY</td> </tr> <tr> <td valign="top" styleCode=" Botrule Toprule Lrule Rrule "> Tacrolimus (N=250)</td> <td valign="top" styleCode=" Botrule Toprule Lrule Rrule "> CBIR (N=250)</td> <td valign="top" styleCode=" Botrule Toprule Lrule Rrule "> Tacrolimus (N=264)</td> <td valign="top" styleCode=" Botrule Toprule Lrule Rrule "> CBIR (N=265)</td> </tr> </thead> <tbody> <tr> <td valign="top" styleCode=" Toprule Lrule Rrule "> <content styleCode="bold"> <content styleCode="underline">Nervous System</content> </content> </td> <td valign="top" styleCode=" Toprule Lrule Rrule "> </td> <td valign="top" styleCode=" Toprule Lrule Rrule "> </td> <td valign="top" styleCode=" Toprule Lrule Rrule "> </td> <td valign="top" styleCode=" Toprule Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Headache (see <content styleCode="bold"> <linkHtml href="#LINK_0ee6cc41-a24f-419a-a1b6-b96984333a74">WARNINGS</linkHtml> </content>)</td> <td valign="top" styleCode=" Lrule Rrule "> 64%</td> <td valign="top" styleCode=" Lrule Rrule "> 60%</td> <td valign="top" styleCode=" Lrule Rrule "> 37%</td> <td valign="top" styleCode=" Lrule Rrule "> 26%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Tremor (see <content styleCode="bold"> <linkHtml href="#LINK_0ee6cc41-a24f-419a-a1b6-b96984333a74">WARNINGS</linkHtml> </content>)</td> <td valign="top" styleCode=" Lrule Rrule "> 56%</td> <td valign="top" styleCode=" Lrule Rrule "> 46%</td> <td valign="top" styleCode=" Lrule Rrule "> 48%</td> <td valign="top" styleCode=" Lrule Rrule "> 32%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Insomnia</td> <td valign="top" styleCode=" Lrule Rrule "> 64%</td> <td valign="top" styleCode=" Lrule Rrule "> 68%</td> <td valign="top" styleCode=" Lrule Rrule "> 32%</td> <td valign="top" styleCode=" Lrule Rrule "> 23%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Paresthesia</td> <td valign="top" styleCode=" Lrule Rrule "> 40%</td> <td valign="top" styleCode=" Lrule Rrule "> 30%</td> <td valign="top" styleCode=" Lrule Rrule "> 17%</td> <td valign="top" styleCode=" Lrule Rrule "> 17%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> <content styleCode="bold"> <content styleCode="underline">Gastrointestinal</content> </content> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Diarrhea</td> <td valign="top" styleCode=" Lrule Rrule "> 72%</td> <td valign="top" styleCode=" Lrule Rrule "> 47%</td> <td valign="top" styleCode=" Lrule Rrule "> 37%</td> <td valign="top" styleCode=" Lrule Rrule "> 27%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Nausea</td> <td valign="top" styleCode=" Lrule Rrule "> 46%</td> <td valign="top" styleCode=" Lrule Rrule "> 37%</td> <td valign="top" styleCode=" Lrule Rrule "> 32%</td> <td valign="top" styleCode=" Lrule Rrule "> 27%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Constipation</td> <td valign="top" styleCode=" Lrule Rrule "> 24%</td> <td valign="top" styleCode=" Lrule Rrule "> 27%</td> <td valign="top" styleCode=" Lrule Rrule "> 23%</td> <td valign="top" styleCode=" Lrule Rrule "> 21%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> LFT Abnormal</td> <td valign="top" styleCode=" Lrule Rrule "> 36%</td> <td valign="top" styleCode=" Lrule Rrule "> 30%</td> <td valign="top" styleCode=" Lrule Rrule "> 6%</td> <td valign="top" styleCode=" Lrule Rrule "> 5%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Anorexia</td> <td valign="top" styleCode=" Lrule Rrule "> 34%</td> <td valign="top" styleCode=" Lrule Rrule "> 24%</td> <td valign="top" styleCode=" Lrule Rrule "> 7%</td> <td valign="top" styleCode=" Lrule Rrule "> 5%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Vomiting</td> <td valign="top" styleCode=" Lrule Rrule "> 27%</td> <td valign="top" styleCode=" Lrule Rrule "> 15%</td> <td valign="top" styleCode=" Lrule Rrule "> 14%</td> <td valign="top" styleCode=" Lrule Rrule "> 11%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> <content styleCode="bold"> <content styleCode="underline">Cardiovascular</content> </content> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Hypertension (see <content styleCode="bold"> <linkHtml href="#LINK_5eada8b8-bd6f-478d-9702-92100321ace3">PRECAUTIONS</linkHtml> </content>)</td> <td valign="top" styleCode=" Lrule Rrule "> 47%</td> <td valign="top" styleCode=" Lrule Rrule "> 56%</td> <td valign="top" styleCode=" Lrule Rrule "> 38%</td> <td valign="top" styleCode=" Lrule Rrule "> 43%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> <content styleCode="bold"> <content styleCode="underline">Urogenital</content> </content> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Kidney Function Abnormal (see <content styleCode="bold"> <linkHtml href="#LINK_0ee6cc41-a24f-419a-a1b6-b96984333a74">WARNINGS</linkHtml> </content>)</td> <td valign="top" styleCode=" Lrule Rrule "> 40%</td> <td valign="top" styleCode=" Lrule Rrule "> 27%</td> <td valign="top" styleCode=" Lrule Rrule "> 36%</td> <td valign="top" styleCode=" Lrule Rrule "> 23%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Creatinine Increased (see <content styleCode="bold"> <linkHtml href="#LINK_0ee6cc41-a24f-419a-a1b6-b96984333a74">WARNINGS</linkHtml> </content>)</td> <td valign="top" styleCode=" Lrule Rrule "> 39%</td> <td valign="top" styleCode=" Lrule Rrule "> 25%</td> <td valign="top" styleCode=" Lrule Rrule "> 24%</td> <td valign="top" styleCode=" Lrule Rrule "> 19%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> BUN Increased (see <content styleCode="bold"> <linkHtml href="#LINK_0ee6cc41-a24f-419a-a1b6-b96984333a74">WARNINGS</linkHtml> </content>)</td> <td valign="top" styleCode=" Lrule Rrule "> 30%</td> <td valign="top" styleCode=" Lrule Rrule "> 22%</td> <td valign="top" styleCode=" Lrule Rrule "> 12%</td> <td valign="top" styleCode=" Lrule Rrule "> 9%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Urinary Tract Infection</td> <td valign="top" styleCode=" Lrule Rrule "> 16%</td> <td valign="top" styleCode=" Lrule Rrule "> 18%</td> <td valign="top" styleCode=" Lrule Rrule "> 21%</td> <td valign="top" styleCode=" Lrule Rrule "> 19%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Oliguria</td> <td valign="top" styleCode=" Lrule Rrule "> 18%</td> <td valign="top" styleCode=" Lrule Rrule "> 15%</td> <td valign="top" styleCode=" Lrule Rrule "> 19%</td> <td valign="top" styleCode=" Lrule Rrule "> 12%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> <content styleCode="bold"> <content styleCode="underline">Metabolic and Nutritional</content> </content> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Hyperkalemia (see <content styleCode="bold"> <linkHtml href="#LINK_0ee6cc41-a24f-419a-a1b6-b96984333a74">WARNINGS</linkHtml> </content>)</td> <td valign="top" styleCode=" Lrule Rrule "> 45%</td> <td valign="top" styleCode=" Lrule Rrule "> 26%</td> <td valign="top" styleCode=" Lrule Rrule "> 13%</td> <td valign="top" styleCode=" Lrule Rrule "> 9%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Hypokalemia</td> <td valign="top" styleCode=" Lrule Rrule "> 29%</td> <td valign="top" styleCode=" Lrule Rrule "> 34%</td> <td valign="top" styleCode=" Lrule Rrule "> 13%</td> <td valign="top" styleCode=" Lrule Rrule "> 16%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Hyperglycemia (see <content styleCode="bold"> <linkHtml href="#LINK_0ee6cc41-a24f-419a-a1b6-b96984333a74">WARNINGS</linkHtml> </content>)</td> <td valign="top" styleCode=" Lrule Rrule "> 47%</td> <td valign="top" styleCode=" Lrule Rrule "> 38%</td> <td valign="top" styleCode=" Lrule Rrule "> 33%</td> <td valign="top" styleCode=" Lrule Rrule "> 22%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Hypomagnesemia</td> <td valign="top" styleCode=" Lrule Rrule "> 48%</td> <td valign="top" styleCode=" Lrule Rrule "> 45%</td> <td valign="top" styleCode=" Lrule Rrule "> 16%</td> <td valign="top" styleCode=" Lrule Rrule "> 9%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> <content styleCode="bold"> <content styleCode="underline">Hemic and Lymphatic</content> </content> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Anemia</td> <td valign="top" styleCode=" Lrule Rrule "> 47%</td> <td valign="top" styleCode=" Lrule Rrule "> 38%</td> <td valign="top" styleCode=" Lrule Rrule "> 5%</td> <td valign="top" styleCode=" Lrule Rrule "> 1%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Leukocytosis</td> <td valign="top" styleCode=" Lrule Rrule "> 32%</td> <td valign="top" styleCode=" Lrule Rrule "> 26%</td> <td valign="top" styleCode=" Lrule Rrule "> 8%</td> <td valign="top" styleCode=" Lrule Rrule "> 8%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Thrombocytopenia</td> <td valign="top" styleCode=" Lrule Rrule "> 24%</td> <td valign="top" styleCode=" Lrule Rrule "> 20%</td> <td valign="top" styleCode=" Lrule Rrule "> 14%</td> <td valign="top" styleCode=" Lrule Rrule "> 19%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> <content styleCode="bold"> <content styleCode="underline">Miscellaneous</content> </content> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Abdominal Pain</td> <td valign="top" styleCode=" Lrule Rrule "> 59%</td> <td valign="top" styleCode=" Lrule Rrule "> 54%</td> <td valign="top" styleCode=" Lrule Rrule "> 29%</td> <td valign="top" styleCode=" Lrule Rrule "> 22%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Pain</td> <td valign="top" styleCode=" Lrule Rrule "> 63%</td> <td valign="top" styleCode=" Lrule Rrule "> 57%</td> <td valign="top" styleCode=" Lrule Rrule "> 24%</td> <td valign="top" styleCode=" Lrule Rrule "> 22%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Fever</td> <td valign="top" styleCode=" Lrule Rrule "> 48%</td> <td valign="top" styleCode=" Lrule Rrule "> 56%</td> <td valign="top" styleCode=" Lrule Rrule "> 19%</td> <td valign="top" styleCode=" Lrule Rrule "> 22%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Asthenia</td> <td valign="top" styleCode=" Lrule Rrule "> 52%</td> <td valign="top" styleCode=" Lrule Rrule "> 48%</td> <td valign="top" styleCode=" Lrule Rrule "> 11%</td> <td valign="top" styleCode=" Lrule Rrule "> 7%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Back Pain</td> <td valign="top" styleCode=" Lrule Rrule "> 30%</td> <td valign="top" styleCode=" Lrule Rrule "> 29%</td> <td valign="top" styleCode=" Lrule Rrule "> 17%</td> <td valign="top" styleCode=" Lrule Rrule "> 17%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Ascites</td> <td valign="top" styleCode=" Lrule Rrule "> 27%</td> <td valign="top" styleCode=" Lrule Rrule "> 22%</td> <td valign="top" styleCode=" Lrule Rrule "> 7%</td> <td valign="top" styleCode=" Lrule Rrule "> 8%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Peripheral Edema</td> <td valign="top" styleCode=" Lrule Rrule "> 26%</td> <td valign="top" styleCode=" Lrule Rrule "> 26%</td> <td valign="top" styleCode=" Lrule Rrule "> 12%</td> <td valign="top" styleCode=" Lrule Rrule "> 14%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> <content styleCode="bold"> <content styleCode="underline">Respiratory System</content> </content> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Pleural Effusion</td> <td valign="top" styleCode=" Lrule Rrule "> 30%</td> <td valign="top" styleCode=" Lrule Rrule "> 32%</td> <td valign="top" styleCode=" Lrule Rrule "> 36%</td> <td valign="top" styleCode=" Lrule Rrule "> 35%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Atelectasis</td> <td valign="top" styleCode=" Lrule Rrule "> 28%</td> <td valign="top" styleCode=" Lrule Rrule "> 30%</td> <td valign="top" styleCode=" Lrule Rrule "> 5%</td> <td valign="top" styleCode=" Lrule Rrule "> 4%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Dyspnea</td> <td valign="top" styleCode=" Lrule Rrule "> 29%</td> <td valign="top" styleCode=" Lrule Rrule "> 23%</td> <td valign="top" styleCode=" Lrule Rrule "> 5%</td> <td valign="top" styleCode=" Lrule Rrule "> 4%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> <content styleCode="bold"> <content styleCode="underline">Skin and Appendages</content> </content> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Pruritus</td> <td valign="top" styleCode=" Lrule Rrule "> 36%</td> <td valign="top" styleCode=" Lrule Rrule "> 20%</td> <td valign="top" styleCode=" Lrule Rrule "> 15%</td> <td valign="top" styleCode=" Lrule Rrule "> 7%</td> </tr> <tr> <td valign="top" styleCode=" Botrule Lrule Rrule "> Rash</td> <td valign="top" styleCode=" Botrule Lrule Rrule "> 24%</td> <td valign="top" styleCode=" Botrule Lrule Rrule "> 19%</td> <td valign="top" styleCode=" Botrule Lrule Rrule "> 10%</td> <td valign="top" styleCode=" Botrule Lrule Rrule "> 4%</td> </tr> </tbody> </table>
adverse reactions table
<table frame="void"> <caption> KIDNEY TRANSPLANTATION: ADVERSE EVENTS OCCURRING IN ≥ 15% OF PATIENTS TREATED WITH TACROLIMUS IN CONJUNCTION WITH AZATHIOPRINE</caption> <col/> <col/> <col/> <thead> <tr> <td valign="top" styleCode=" Botrule Toprule Lrule Rrule "> </td> <td valign="top" styleCode=" Botrule Toprule Lrule Rrule "> Tacrolimus (N=205)</td> <td valign="top" styleCode=" Botrule Toprule Lrule Rrule "> CBIR (N=207)</td> </tr> </thead> <tbody> <tr> <td valign="top" styleCode=" Toprule Lrule Rrule "> <content styleCode="bold"> <content styleCode="underline">Nervous System</content> </content> </td> <td valign="top" styleCode=" Toprule Lrule Rrule "> </td> <td valign="top" styleCode=" Toprule Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Tremor (see <content styleCode="bold"> <linkHtml href="#LINK_0ee6cc41-a24f-419a-a1b6-b96984333a74">WARNINGS</linkHtml> </content>)</td> <td valign="top" styleCode=" Lrule Rrule "> 54%</td> <td valign="top" styleCode=" Lrule Rrule "> 34%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Headache (see <content styleCode="bold"> <linkHtml href="#LINK_0ee6cc41-a24f-419a-a1b6-b96984333a74">WARNINGS</linkHtml> </content>)</td> <td valign="top" styleCode=" Lrule Rrule "> 44%</td> <td valign="top" styleCode=" Lrule Rrule "> 38%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Insomnia</td> <td valign="top" styleCode=" Lrule Rrule "> 32%</td> <td valign="top" styleCode=" Lrule Rrule "> 30%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Paresthesia</td> <td valign="top" styleCode=" Lrule Rrule "> 23%</td> <td valign="top" styleCode=" Lrule Rrule "> 16%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Dizziness</td> <td valign="top" styleCode=" Lrule Rrule "> 19%</td> <td valign="top" styleCode=" Lrule Rrule "> 16%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> <content styleCode="bold"> <content styleCode="underline">Gastrointestinal</content> </content> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Diarrhea</td> <td valign="top" styleCode=" Lrule Rrule "> 44%</td> <td valign="top" styleCode=" Lrule Rrule "> 41%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Nausea</td> <td valign="top" styleCode=" Lrule Rrule "> 38%</td> <td valign="top" styleCode=" Lrule Rrule "> 36%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Constipation</td> <td valign="top" styleCode=" Lrule Rrule "> 35%</td> <td valign="top" styleCode=" Lrule Rrule "> 43%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Vomiting</td> <td valign="top" styleCode=" Lrule Rrule "> 29%</td> <td valign="top" styleCode=" Lrule Rrule "> 23%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Dyspepsia</td> <td valign="top" styleCode=" Lrule Rrule "> 28%</td> <td valign="top" styleCode=" Lrule Rrule "> 20%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> <content styleCode="bold"> <content styleCode="underline">Cardiovascular</content> </content> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Hypertension (see <content styleCode="bold"> <linkHtml href="#LINK_5eada8b8-bd6f-478d-9702-92100321ace3">PRECAUTIONS</linkHtml> </content>)</td> <td valign="top" styleCode=" Lrule Rrule "> 50%</td> <td valign="top" styleCode=" Lrule Rrule "> 52%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Chest pain</td> <td valign="top" styleCode=" Lrule Rrule "> 19%</td> <td valign="top" styleCode=" Lrule Rrule "> 13%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> <content styleCode="bold"> <content styleCode="underline">Urogenital</content> </content> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Creatinine Increased (see <content styleCode="bold"> <linkHtml href="#LINK_0ee6cc41-a24f-419a-a1b6-b96984333a74">WARNINGS</linkHtml> </content>)</td> <td valign="top" styleCode=" Lrule Rrule "> 45%</td> <td valign="top" styleCode=" Lrule Rrule "> 42%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Urinary Tract Infection</td> <td valign="top" styleCode=" Lrule Rrule "> 34%</td> <td valign="top" styleCode=" Lrule Rrule "> 35%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> <content styleCode="bold"> <content styleCode="underline">Metabolic and Nutritional</content> </content> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Hypophosphatemia</td> <td valign="top" styleCode=" Lrule Rrule "> 49%</td> <td valign="top" styleCode=" Lrule Rrule "> 53%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Hypomagnesemia</td> <td valign="top" styleCode=" Lrule Rrule "> 34%</td> <td valign="top" styleCode=" Lrule Rrule "> 17%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Hyperlipemia</td> <td valign="top" styleCode=" Lrule Rrule "> 31%</td> <td valign="top" styleCode=" Lrule Rrule "> 38%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Hyperkalemia (see <content styleCode="bold"> <linkHtml href="#LINK_0ee6cc41-a24f-419a-a1b6-b96984333a74">WARNINGS</linkHtml> </content>)</td> <td valign="top" styleCode=" Lrule Rrule "> 31%</td> <td valign="top" styleCode=" Lrule Rrule "> 32%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Diabetes Mellitus (see <content styleCode="bold"> <linkHtml href="#LINK_0ee6cc41-a24f-419a-a1b6-b96984333a74">WARNINGS</linkHtml> </content>)</td> <td valign="top" styleCode=" Lrule Rrule "> 24%</td> <td valign="top" styleCode=" Lrule Rrule "> 9%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Hypokalemia</td> <td valign="top" styleCode=" Lrule Rrule "> 22%</td> <td valign="top" styleCode=" Lrule Rrule "> 25%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Hyperglycemia (see <content styleCode="bold"> <linkHtml href="#LINK_0ee6cc41-a24f-419a-a1b6-b96984333a74">WARNINGS</linkHtml> </content>)</td> <td valign="top" styleCode=" Lrule Rrule "> 22%</td> <td valign="top" styleCode=" Lrule Rrule "> 16%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Edema</td> <td valign="top" styleCode=" Lrule Rrule "> 18%</td> <td valign="top" styleCode=" Lrule Rrule "> 19%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> <content styleCode="bold"> <content styleCode="underline">Hemic and Lymphatic</content> </content> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Anemia</td> <td valign="top" styleCode=" Lrule Rrule "> 30%</td> <td valign="top" styleCode=" Lrule Rrule "> 24%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Leukopenia</td> <td valign="top" styleCode=" Lrule Rrule "> 15%</td> <td valign="top" styleCode=" Lrule Rrule "> 17%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> <content styleCode="bold"> <content styleCode="underline">Miscellaneous</content> </content> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Infection</td> <td valign="top" styleCode=" Lrule Rrule "> 45%</td> <td valign="top" styleCode=" Lrule Rrule "> 49%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Peripheral Edema</td> <td valign="top" styleCode=" Lrule Rrule "> 36%</td> <td valign="top" styleCode=" Lrule Rrule "> 48%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Asthenia</td> <td valign="top" styleCode=" Lrule Rrule "> 34%</td> <td valign="top" styleCode=" Lrule Rrule "> 30%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Abdominal Pain</td> <td valign="top" styleCode=" Lrule Rrule "> 33%</td> <td valign="top" styleCode=" Lrule Rrule "> 31%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Pain</td> <td valign="top" styleCode=" Lrule Rrule "> 32%</td> <td valign="top" styleCode=" Lrule Rrule "> 30%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Fever</td> <td valign="top" styleCode=" Lrule Rrule "> 29%</td> <td valign="top" styleCode=" Lrule Rrule "> 29%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Back Pain</td> <td valign="top" styleCode=" Lrule Rrule "> 24%</td> <td valign="top" styleCode=" Lrule Rrule "> 20%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> <content styleCode="bold"> <content styleCode="underline">Respiratory System</content> </content> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Dyspnea</td> <td valign="top" styleCode=" Lrule Rrule "> 22%</td> <td valign="top" styleCode=" Lrule Rrule "> 18%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Cough Increased</td> <td valign="top" styleCode=" Lrule Rrule "> 18%</td> <td valign="top" styleCode=" Lrule Rrule "> 15%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> <content styleCode="bold"> <content styleCode="underline">Musculoskeletal</content> </content> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Arthralgia</td> <td valign="top" styleCode=" Lrule Rrule "> 25%</td> <td valign="top" styleCode=" Lrule Rrule "> 24%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> <content styleCode="bold"> <content styleCode="underline">Skin</content> </content> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> <td valign="top" styleCode=" Lrule Rrule "> </td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Rash</td> <td valign="top" styleCode=" Lrule Rrule "> 17%</td> <td valign="top" styleCode=" Lrule Rrule "> 12%</td> </tr> <tr> <td valign="top" styleCode=" Botrule Lrule Rrule "> Pruritus</td> <td valign="top" styleCode=" Botrule Lrule Rrule "> 15%</td> <td valign="top" styleCode=" Botrule Lrule Rrule "> 7%</td> </tr> </tbody> </table>
adverse reactions table
<table frame="void"> <caption> KIDNEY TRANSPLANTATION: ADVERSE EVENTS OCCURRING IN ≥ 10% OF TACROLIMUS-TREATED PATIENTS</caption> <col/> <col/> <col/> <col/> <thead> <tr> <td valign="top" styleCode=" Botrule Lrule Rrule "> </td> <td align="center" valign="top" styleCode=" Botrule Lrule Rrule "> <content styleCode="bold">Tacrolimus</content> <content styleCode="bold"> </content> <content styleCode="bold">(Group C)</content> <content styleCode="bold"> </content> <content styleCode="bold">(N=403)</content> </td> <td align="center" valign="top" styleCode=" Botrule Lrule Rrule "> <content styleCode="bold">Cyclosporine</content> <content styleCode="bold"> </content> <content styleCode="bold">(Group A)</content> <content styleCode="bold"> </content> <content styleCode="bold">(N=384)</content> </td> <td align="center" valign="top" styleCode=" Botrule Lrule Rrule "> <content styleCode="bold">Cyclosporine</content> <content styleCode="bold"> </content> <content styleCode="bold">(Group B)</content> <content styleCode="bold"> </content> <content styleCode="bold">(N=408)</content> </td> </tr> </thead> <tfoot> <tr> <td valign="top" colspan="4"> *Study 1 was conducted entirely outside of the United States. Such studies often report a lower incidence of adverse events in comparison to US studies. </td> </tr> </tfoot> <tbody> <tr> <td valign="top" styleCode=" Toprule Lrule Rrule "> Anemia</td> <td align="center" valign="top" styleCode=" Toprule Lrule Rrule "> 17%</td> <td align="center" valign="top" styleCode=" Toprule Lrule Rrule "> 19%</td> <td align="center" valign="top" styleCode=" Toprule Lrule Rrule "> 17%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Leucopenia</td> <td align="center" valign="top" styleCode=" Lrule Rrule "> 13%</td> <td align="center" valign="top" styleCode=" Lrule Rrule "> 10%</td> <td align="center" valign="top" styleCode=" Lrule Rrule "> 10%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Diarrhea</td> <td align="center" valign="top" styleCode=" Lrule Rrule "> 25%</td> <td align="center" valign="top" styleCode=" Lrule Rrule "> 16%</td> <td align="center" valign="top" styleCode=" Lrule Rrule "> 13%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Edema peripheral</td> <td align="center" valign="top" styleCode=" Lrule Rrule "> 11%</td> <td align="center" valign="top" styleCode=" Lrule Rrule "> 12%</td> <td align="center" valign="top" styleCode=" Lrule Rrule "> 13%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Urinary tract infection</td> <td align="center" valign="top" styleCode=" Lrule Rrule "> 24%</td> <td align="center" valign="top" styleCode=" Lrule Rrule "> 28%</td> <td align="center" valign="top" styleCode=" Lrule Rrule "> 24%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Hyperlipidemia</td> <td align="center" valign="top" styleCode=" Lrule Rrule "> 10%</td> <td align="center" valign="top" styleCode=" Lrule Rrule "> 15%</td> <td align="center" valign="top" styleCode=" Lrule Rrule "> 13%</td> </tr> <tr> <td valign="top" styleCode=" Lrule Rrule "> Hypertension (see <content styleCode="bold"> <linkHtml href="#LINK_5eada8b8-bd6f-478d-9702-92100321ace3">PRECAUTIONS</linkHtml> </content>)</td> <td align="center" valign="top" styleCode=" Lrule Rrule "> 13%</td> <td align="center" valign="top" styleCode=" Lrule Rrule "> 14%</td> <td align="center" valign="top" styleCode=" Lrule Rrule "> 12%</td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.